12:13 PM EST - Gemina Laboratories : Provides an update on its current activities related to the development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company's patented breakthrough chemistry platform. Following the previously announced prototype design freeze for use in saliva and the transfer of the prototype to International Point of Care, the company is pleased to announce the completion of another important milestone, namely: design freeze for shallow nasal swab testing. Nasal swabs have become the leading method for large scale rapid testing globally. Gemina Laboratories
shares C.GLAB are trading unchanged at $0.50.
